YU50402A - Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze - Google Patents

Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze

Info

Publication number
YU50402A
YU50402A YU50402A YUP50402A YU50402A YU 50402 A YU50402 A YU 50402A YU 50402 A YU50402 A YU 50402A YU P50402 A YUP50402 A YU P50402A YU 50402 A YU50402 A YU 50402A
Authority
YU
Yugoslavia
Prior art keywords
substituted lower
compounds
substituted
nr9r10
cyano
Prior art date
Application number
YU50402A
Other languages
English (en)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Vara Prasad Venkata N. Josyula
Dennis Joseph Mcnamara
Peter Laurence Toogood
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of YU50402A publication Critical patent/YU50402A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Opisana su jedinjenja formule (I), gde su R2, R7, R13, R14 i R15, nezavisno, vodonik ili (ne)supstituisani nizi alkil, (ne)supstituisani nizi alkenil, (ne)supstituisani nizi alkil, ili (ne)supstituisani -(CH2)nR12; R5 je halogen, cijano, nitro, -R9, -NR9R10 ili -OR9; R6 je halogen, cijano, nitro, -R9, -NR9R10, -OR9, -CO2R9, -COR9, -CONR9R10, -NR9COR10, (ne)supstituisani nizi alkenil, ili (ne)supstituisani nizi alkinil; R8 je -CO2R13, -COR13, -CONR13R14, -CSNR13R14, -C(NR13)NR14R15, -SO3R13, -SO2R13, -SO3NR13R14, -PO3R13R14, -POR13R14, -PO(NR13R14)2; R9 i R10 su nezavisno vodonik ili (ne)supstituisani nizi alkil; R11 je heteroaril ili heterociklil grupa; R12 je cikloalkil, heterociklil, aril, ili heteroaril grupa; n je 0, 1, 2 ili 3. Ova jedinjenja i njihovi farmaceutski preparati su korisna za tretiranje celijskih proliferativnih poremecaja, kao sto su kancer i restenoza. Ova jedinjenja su snazni inhibitori cdk i kinaza posredovanih faktorom rasta.
YU50402A 2000-01-25 2001-01-23 Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze YU50402A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
YU50402A true YU50402A (sh) 2005-11-28

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
YU50402A YU50402A (sh) 2000-01-25 2001-01-23 Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze

Country Status (34)

Country Link
EP (1) EP1254137A1 (sh)
JP (1) JP4047010B2 (sh)
KR (1) KR20020065939A (sh)
CN (1) CN1395578A (sh)
AP (1) AP2002002586A0 (sh)
AR (1) AR030044A1 (sh)
AU (1) AU2542501A (sh)
BG (1) BG106850A (sh)
BR (1) BR0107751A (sh)
CA (1) CA2397961C (sh)
CO (1) CO5261549A1 (sh)
CR (1) CR6706A (sh)
CZ (1) CZ20022475A3 (sh)
DZ (1) DZ3266A1 (sh)
EA (1) EA200200643A1 (sh)
EE (1) EE200200405A (sh)
GT (1) GT200100016A (sh)
HN (1) HN2001000013A (sh)
HU (1) HUP0204141A3 (sh)
IL (1) IL150545A0 (sh)
IS (1) IS6443A (sh)
MA (1) MA26868A1 (sh)
MX (1) MXPA02007221A (sh)
NO (1) NO20023527L (sh)
OA (1) OA12161A (sh)
PA (1) PA8510701A1 (sh)
PE (1) PE20011066A1 (sh)
PL (1) PL356802A1 (sh)
SK (1) SK10632002A3 (sh)
SV (1) SV2002000294A (sh)
TN (1) TNSN01014A1 (sh)
WO (1) WO2001055147A1 (sh)
YU (1) YU50402A (sh)
ZA (1) ZA200205879B (sh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
CN1646131A (zh) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006032452A1 (en) * 2004-09-21 2006-03-30 F. Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
WO2006104917A2 (en) 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
ATE449097T1 (de) * 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0614804A2 (pt) 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
KR20110093923A (ko) * 2008-12-01 2011-08-18 메르크 파텐트 게엠베하 암에 대한 오토탁신 저해제로서의 ２,５-디아미노-치환된 피리도 ［４,３-ｄ］피리미딘
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
EP2968331B1 (en) * 2013-03-14 2020-07-01 Icahn School of Medicine at Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU711426B2 (en) * 1994-11-14 1999-10-14 Warner-Lambert Company 6-aryl pyrido(2,3-d)pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
ES2310039T3 (es) * 1998-05-26 2008-12-16 Warner-Lambert Company Llc Pirimidinas biciclicas y 3,4-dihidropirimidinas biciclicas como inhibidores de la proliferacion celular.

Also Published As

Publication number Publication date
CA2397961C (en) 2008-08-26
SV2002000294A (es) 2002-07-16
PE20011066A1 (es) 2001-10-22
AR030044A1 (es) 2003-08-13
BG106850A (bg) 2003-02-28
HUP0204141A3 (en) 2005-03-29
MXPA02007221A (es) 2002-11-29
NO20023527L (no) 2002-09-10
ZA200205879B (en) 2003-09-29
IL150545A0 (en) 2003-02-12
PA8510701A1 (es) 2002-12-11
HN2001000013A (es) 2001-06-18
AU2542501A (en) 2001-08-07
CA2397961A1 (en) 2001-08-02
TNSN01014A1 (fr) 2005-11-10
CR6706A (es) 2005-04-04
IS6443A (is) 2002-06-25
AP2002002586A0 (en) 2002-09-30
EA200200643A1 (ru) 2002-12-26
PL356802A1 (en) 2004-07-12
NO20023527D0 (no) 2002-07-24
SK10632002A3 (sk) 2003-06-03
CO5261549A1 (es) 2003-03-31
HUP0204141A2 (hu) 2003-04-28
OA12161A (en) 2006-05-08
GT200100016A (es) 2001-10-19
EE200200405A (et) 2003-12-15
DZ3266A1 (fr) 2001-08-02
BR0107751A (pt) 2002-11-12
EP1254137A1 (en) 2002-11-06
JP4047010B2 (ja) 2008-02-13
WO2001055147A1 (en) 2001-08-02
CZ20022475A3 (cs) 2003-03-12
KR20020065939A (ko) 2002-08-14
CN1395578A (zh) 2003-02-05
JP2003523357A (ja) 2003-08-05
MA26868A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
YU50402A (sh) Pirido(2,3-d)pirimidin-2,7-diaminski inhibitori kinaze
BG106594A (en) Pteridinones as kinase inhibitors
RU2591191C2 (ru) Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
AP2000001964A0 (en) Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation.
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
CA2997039C (en) 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof
SE0202463D0 (sv) Novel compounds
RU2005127052A (ru) Соединения тиенопиримидина и их применение
GEP20156282B (en) Compounds and compositions as protein kinase inhibitors
NZ627709A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
BG107161A (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
ZA200206191B (en) Pyrimidine compounds.
BR112015002152B1 (pt) Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
UY27198A1 (es) Nuevos compuestos antiinflamatorios de bencimidazol
HUP0300798A2 (hu) Szubsztituált triazolopirimidin-származékok és alkalmazásuk rákellenes hatóanyagként és ezeket tartalmazó gyógyszerkészítmények
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
EP1233950A4 (en) 3,4-DIHYDRO (1H) CHINAZOLIN 2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
MXPA03004023A (es) Compuestos quimicos.
DK0888356T3 (da) Kondenserede 2,3-benzodiazepinderivater og deres anvendelse som AMPA-receptohaemmere
AR027035A1 (es) Pirroles sustituidos
TH53887A (th) ไพริโด (2,3-d) , ไพริมิดีน-2.7- ไดเอมีนที่เป็นสารยับยั้งคิเนส
CN117751104A (zh) 一类具有激酶抑制功能的化合物及其制备和应用